Announcement • Apr 15
D&D Pharmatech Inc. announced that it expects to receive KRW 226.5 billion in funding from DS Asset Management Co., Ltd, Korea Investment & Securities Co., Ltd., Weiss Asset Management LP and includes other investors.
D&D Pharmatech Inc. announced private placement to issue Zero Coupon Series 2 Bearer-type, unsecured private placement convertible bonds due April 30, 2031 for gross proceeds of KRW 226,500,000,000 on April 15, 2026. The bonds are zero coupon with no yield to maturity and will mature on April 30, 2031. The bond is 100% convertible into 2,913,691 shares at a conversion price of KRW 77,736 at a conversion period of April 30, 2027 to March 30, 2031. The company will issue bonds by third party allotment and the bonds are restricted for 1 year. The transaction includes participation from Kiwoom-DS Investment Biohealth Fund for KRW 5,000,000,000, IBK Financial Group-DS Green Finance Fund for KRW 9,500,000,000, DS Investment Healthcare New Technology Fund No. 6 for KRW 50,000,000,000, Ds Investment & Securities Co.,Ltd. for KRW 10,000,000,000, Korea Investment & Securities Co., Ltd. for KRW 6,000,000,000, Aquila Investments XX for KRW 16,000,000,000, Brookdale International Partners, L.P. for KRW 17,500,000,000, Brookdale Global Opportunity Fund for KRW 32,500,000,000, NH Daily Biohealth PEF for KRW 10,000,000,000, Loftyrock-Wayne Global Pharmatech New Technology Fund for KRW 10,000,000,000 Korea Investment & Securities Co., Ltd. (in its capacity as the trustee of Fund 1 for KRW 2,100,000,000; Fund 2 for KRW 2,100,000,000; Fund 3 for KRW 550,000,000; Fund 14 for KRW 2,400,000,000; Fund 16 for KRW 1,000,000,000; Fund 29 for KRW 1,500,000,000; Fund 30 for KRW 1,000,000,000) for a total of KRW 10,650,000,000, Samsung Securities Co., Ltd. (in its capacity as the trustee of Fund 4 for KRW 1,250,000,000; Fund 5 for KRW 2,000,000,000; Fund 6 for KRW 1,500,000,000; Fund 7 for KRW 1,500,000,000; Fund 8 for KRW 1,000,000,000; Fund 20 for KRW 2,500,000,000; Fund 22 for KRW 1,500,000,000; Fund 26 for KRW 3,000,000,000; Fund 36 for KRW 1,500,000,000; Fund 37 for KRW 500,000,000) for a total of KRW 16,250,000,000, KB Securities Co., Ltd. (in its capacity as the trustee of Fund 9 for KRW 5,000,000,000; Fund 10 for KRW 2,700,000,000; Fund 18 for KRW 1,600,000,000) for a total of KRW 9,300,000,000, NH Investment & Securities Co., Ltd. (in its capacity as the trustee of Fund 11 for KRW 450,000,000; Fund 12 for KRW 300,000,000; Fund 13 for KRW 1,550,000,000; Fund 15 for KRW 1,100,000,000; Fund 17 for KRW 800,000,000; Fund 21 for KRW 2,500,000,000; Fund 23 for KRW 2,000,000,000; Fund 27 for KRW 2,000,000,000; Fund 28 for KRW 3,000,000,000; Fund 31 for KRW 1,400,000,000; Fund 32 for KRW 1,600,000,000; Fund 33 for KRW 850,000,000; Fund 34 for KRW 900,000,000; Fund 35 for KRW 250,000,000) for a total of KRW 18,700,000,000, Mirae Asset Securities Co., Ltd. (in its capacity as the trustee of Fund 24 for KRW 1,300,000,000; Fund 25 for KRW 700,000,000) for a total of KRW 2,000,000,000, Shinhan Investment & Securities Co., Ltd. (in its capacity as the trustee of Fund 19 for KRW 1,600,000,000; Fund 38 for KRW 500,000,000; Fund 39 for KRW 1,000,000,000) for a total of KRW 3,100,000,000.The transaction is approved by board of directors of the company and is expected to close on April 30, 2026.